RSPH14

Across TCGA pan-cancer cohorts, RSPH14 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RSPH14 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RSPH14 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RSPH14 expression acts as an unfavorable survival marker.

ESCA, PRAD, and UCEC are the cancer types where RSPH14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.211	0.876	.028	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RSPH14–ESCA (OS)

Open the ESCA breakdown →